Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 17,643 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Open Label Clear all
Completed Phase 2Phase 3 Interventional

Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures

NCT00151879
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
SPM 927
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 24, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Lesinurad Monotherapy Extension Study in Gout

NCT01650246
View directory record Official record
Conditions
Gout
Interventions
lesinurad
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
57
States / cities
Birmingham, Alabama • Glendale, Arizona • Peoria, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 24, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer

NCT00867503
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Bendamustine HCL
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 24, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee

NCT00531427
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis of the Knee
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
87
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 24, 2026, 9:42 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

NCT05385783
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CYB003, Psychotherapy, Placebo, Psychological Support
Drug · Behavioral
Lead sponsor
Cybin IRL Limited
Industry
Eligibility
21 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 24, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923

NCT04805983
View directory record Official record
Conditions
Alzheimer Disease
Interventions
BMS-984923
Drug
Lead sponsor
Yale University
Other
Eligibility
50 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 24, 2026, 9:42 PM EDT
Not listed Phase 2 Interventional

Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily

NCT00002241
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Lamivudine, Stavudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 24, 2026, 9:42 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain

NCT02101554
View directory record Official record
Conditions
Moderate-severe Pain
Interventions
Ages 7-11, ages 12-17
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Irvine, California • Los Angeles, California • Orange, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Oct 24, 2026, 9:42 PM EDT
Completed Phase 4 Interventional Results available

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

NCT04085172
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
20
States / cities
Dothan, Alabama • Anaheim, California • Imperial, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 24, 2026, 9:42 PM EDT
Completed Phase 4 Interventional

The Young Adult and Pediatric Bipolar Study

NCT00350857
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Extended-Release Carbamazepine
Drug
Lead sponsor
Validus Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
26
States / cities
Altamonte Springs, Florida • Fort Lauderdale, Florida • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2014 · Synced Oct 24, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

NCT01308567
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabazitaxel (XRP6258), Docetaxel (XRP6976), Prednisone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
32
States / cities
Muscle Shoals, Alabama • Anaheim, California • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 24, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fruquintinib Hepatic Impairment Study

NCT05216367
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Fruquintinib
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 24, 2026, 9:42 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease

NCT04833907
View directory record Official record
Conditions
Canavan Disease
Interventions
rAAV-Olig001-ASPA, Levetiracetam, Prednisone
Drug
Lead sponsor
Myrtelle Inc.
Industry
Eligibility
3 Months to 60 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 24, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults

NCT00192465
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MEDI-524 (Numax-TM)
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2009 · Synced Oct 24, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome

NCT04873934
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Inclisiran
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
88
States / cities
Jonesboro, Arkansas • Bakersfield, California • Fresno, California + 75 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 24, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

NCT00192309
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T, TIV, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 24, 2026, 9:42 PM EDT
Terminated Phase 2 Interventional Results available

The Lumen Study: Comparing Devices for Patients With Symptomatic Femoro-popliteal Chronic Total Occlusion (CTO)

NCT02145299
View directory record Official record
Conditions
Symptomatic Femoro-popliteal Chronic Total Occlusion
Interventions
TruePath CTO Device, CROSSER CTO Device
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 24, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers

NCT02663999
View directory record Official record
Conditions
Healthy
Interventions
diazepam nasal spray
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 24, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants

NCT05626439
View directory record Official record
Conditions
Healthy Participants
Interventions
Staccato alprazolam, Oral alprazolam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 24, 2026, 9:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of a New Dressing for Use With Topical Medications

NCT00234728
View directory record Official record
Conditions
Psoriasis
Interventions
Occlusive dressing
Device
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2008 · Synced Oct 24, 2026, 9:42 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Prophylactic Vs. Therapeutic Use of Uroxatrol in Men Undergoing Brachytherapy

NCT00201630
View directory record Official record
Conditions
Prostate Cancer
Interventions
Uroxatrol (drug)
Drug
Lead sponsor
New York Prostate Institute
Other
Eligibility
0 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Oceanside, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2005 · Synced Oct 24, 2026, 9:42 PM EDT
Not listed Phase 4 Interventional

Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)

NCT04245436
View directory record Official record
Conditions
Anxiety, Depressive Symptoms
Interventions
Duloxetine, Escitalopram
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 24, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Results available

Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

NCT03897036
View directory record Official record
Conditions
Carcinoma, Basal Cell
Interventions
CX-4945
Drug
Lead sponsor
Senhwa Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
6
States / cities
Scottsdale, Arizona • Aurora, Colorado • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 24, 2026, 9:42 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
58
States / cities
Fresno, California • San Diego, California • Santa Barbara, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 24, 2026, 9:42 PM EDT